RxDoctor Payments DataLook up a doctor →

Hans Lee, MD

Internal Medicine · Houston, TXNPI 1144470758

Payments from drug & device makers

$11,656,378in general payments, 2019–2025

Across 687 payments — averaging $16,967 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron$4.6M
  • Takeda Pharmaceuticals U.S.A., Inc.$3.6M
  • Amgen$1.1M
  • GSK$836K
  • Janssen Research & Development, LLC$650K
  • Menarini Silicon Biosystems, Inc.$289K
  • plus $562K from 33 others
$72,399in research payments, 2019–2025

Across 68 payments — averaging $1064.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bristol Myers Squibb$35K
  • Regeneron$20K
  • Takeda Pharmaceuticals U.S.A., Inc.$17K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Regeneron133$4,614,484
Takeda Pharmaceuticals U.S.A., Inc.154$3,573,816
Amgen35$1,131,048
GSK68$836,128
Janssen Research & Development, LLC55$649,732
Menarini Silicon Biosystems, Inc.62$288,761
Bristol Myers Squibb25$262,738
AstraZeneca(2 entities)9$134,321
Sanofi15$43,100
E.r. Squibb & Sons, L.L.C.15$29,764
Johnson & Johnson(2 entities)27$23,122
Modernatx, Inc.2$20,542
Janssen Scientific Affairs, LLC17$17,260
Pfizer10$14,555
AbbVie9$6,422
Adaptive Biotechnologies Corporation2$2,539
Karyopharm Therapeutics Inc.3$2,523
Genentech, Inc.2$2,200
Janssen Global Services, LLC4$1,871
Legend Biotech USA Inc.8$586
Regeneron Healthcare Solutions, Inc.7$284
Daiichi Sankyo Inc.3$76
Astrazeneca UK Limited1$52
F. Hoffmann-la Roche AG1$50
Beone Medicines USA, Inc.2$46
EMD Serono, Inc.2$40
Novocure Inc.2$35
Genentech USA, Inc.2$34
Caris MPI, Inc.2$31
Genmab U.S., Inc.1$25
Avyxa Pharma, LLC1$25
Eisai Inc.1$24
Merck1$24
Ipsen Biopharmaceuticals, Inc1$21
Seagen Inc.1$21
Exelixis Inc.1$21
Invivyd Inc1$20
Celltrion USA Inc.1$20
Tempus AI, Inc1$17

How this compares

$11,656,378 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas →

Medicare billing

Part B allowed, 2024
$110,946
Medicare patients
328
Services billed
1,001

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Houston

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →